Compare Hafnia Limited Common Shares (HAFN) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hafnia Limited Common Shares vs Mesoblast Limited — how do they compare? Hafnia Limited Common Shares trades at $10.59 (market cap $5.76B), while Mesoblast Limited trades at $13.76 (market cap $1.83B). The key difference: Hafnia Limited Common Shares is far larger — about 3.1× Mesoblast Limited's market cap, and Hafnia Limited Common Shares pays a 10.24% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hafnia Limited Common Shares for 0 Days and Mesoblast Limited for 15 Days on average.
| HAFN | MESO | |
|---|---|---|
Market Cap | $5.76B | $1.83B |
Volume | 1,835,725 | 259,445 |
Sector | Industrials | Health |
52-Week High | $10.92 | $20.96 |
52-Week Low | $5.21 | $13.19 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $6.37B | $1.91B |
Dividend Yield | 10.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HAFN trades at $10.85, down 0.64% on the day, with a neutral technical signal. The company shows strong fundamentals, with a P/E of 8.35 and net income margin of 24.7%. Recent earnings have consistently beaten expectations, and analysts maintain a 100% buy rating. Key developments include a CEO transition and strategic acquisitions.
Outlook is positive due to robust profitability and growth projections, with 2026 revenue expected to reach $2.7B. Risks include market volatility and execution of new strategies. The stock presents a value opportunity with upside potential, supported by strong cash flow and institutional confidence.
MESO trades at $13.895, down 2.63% with bearish technical signals. The company reported substantial revenue growth to $120M in 2026 but remains unprofitable with a net margin of -47.82%. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant milestones. The stock shows mixed sentiment with 45% analyst buy ratings against bearish technical indicators.
While MESO demonstrates strong revenue growth potential and pipeline progress, persistent losses and negative profitability metrics present substantial risk. The company's cash position of $161M provides runway, but investors face volatility from clinical trial outcomes and path to profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hafnia Limited Common Shares
Hafnia Limited owns and operates a fleet of product and chemical tankers that transport refined oil products, vegetable oils, and chemicals for oil and chemical companies worldwide, across the Long Range, Medium Range, and Handy tanker segments, headquartered in Singapore.
Read more on HAFN →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
